Evidence map›Paper›PMID 38414746›Full record

ArticleFrontiers in oncology2024

Combined antiviral therapy as effective and feasible option in allogenic hematopoietic stem cell transplantation during SARS-COV-2 infection: a case report.

Serena Vita, Alessandra D'Abramo, Andrea Coppola, Chiara Farroni, Anna Paola Iori, Francesca Faraglia, Alessandro Sette, Alba Grifoni, Cecilia Lindestam Arlehamn, Michele Bibas and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Antiviral and Monoclonal Antibody Combination Therapy in Haematological Patients in the Omicron Era.Mediterranean journal of hematology and infectious diseases · 2024
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Serena VitaClinical Department, National Institute for Infectious Diseases 'Lazzaro Spallanzani' Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Alessandra D'AbramoClinical Department, National Institute for Infectious Diseases 'Lazzaro Spallanzani' Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Andrea CoppolaClinical Department, National Institute for Infectious Diseases 'Lazzaro Spallanzani' Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Chiara FarroniClinical Department, National Institute for Infectious Diseases 'Lazzaro Spallanzani' Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Anna Paola IoriPoliclinico Umberto I, Sapienza University of Rome, Rome, Italy.
Francesca FaragliaClinical Department, National Institute for Infectious Diseases 'Lazzaro Spallanzani' Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Alessandro SetteCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, United States.
Alba GrifoniCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, United States.
Cecilia Lindestam ArlehamnCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, United States.
Michele BibasClinical Department, National Institute for Infectious Diseases 'Lazzaro Spallanzani' Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Delia GolettiClinical Department, National Institute for Infectious Diseases 'Lazzaro Spallanzani' Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Emanuele NicastriClinical Department, National Institute for Infectious Diseases 'Lazzaro Spallanzani' Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here we describe the case of a 51 years old Italian woman with acute lymphoblastic leukemia who underwent to hematopoietic stem cell transplantation (HSCT) during SARS-COV-2 infection. She presented a prolonged COVID-19 successfully treated with dual anti SARS-COV-2 antiviral plus monoclonal antibody therapy.

Indexed as

antigen-specific responseantiviralsdual antiviral therapyHSCTimmunocompromisedprolonged infectionSARS-CoV-2 infection

Identifiers

PMID38414746
PMCPMC10896944

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.